Ariad Pharmaceuticals (NASDAQ:ARIA) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 48,055,172 shares, a growth of 16.0% from the June 13th total of 41,432,857 shares, Stock Ratings Network reports. Approximately 26.6% of the shares of the stock are sold short. Based on an average trading volume of 7,279,284 shares, the days-to-cover ratio is presently 6.6 days.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “positive” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 2nd. Separately, analysts at JMP Securities reiterated a “market outperform” rating on shares of Ariad Pharmaceuticals in a research note on Thursday, May 8th. They now have a $8.00 price target on the stock, down previously from $10.00. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the company. Ariad Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $7.10.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 5.87 on Tuesday. Ariad Pharmaceuticals has a 52 week low of $2.15 and a 52 week high of $23.00. The stock has a 50-day moving average of $6.44 and a 200-day moving average of $7.23. The company’s market cap is $1.097 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its earnings results on Wednesday, May 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $10.41 million. During the same quarter in the previous year, the company posted ($0.36) earnings per share. The company’s revenue for the quarter was up 81.5% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.04 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.